Abstract: The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
July 14, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
Abstract: A process for the recovery of unsaturated fatty acids with at least 16 carbon atoms in the molecule or a derivative of such a fatty acid from a mixture of fatty acids and/or fatty acid derivatives by column chromatography with supercritical or liquid carbon dioxide as the mobile phase comprises using aluminum oxide, optionally pretreated with alkali, as the stationary phase. The pre-treatment of the aluminum oxide is conveniently effected by contacting the particulate aluminum oxide with an aqueous solution of an alkali metal or alkaline earth metal hydroxide, optionally supplemented with a water-miscible or water-soluble organic solvent, in the pH range of about 10 to about 13 over several hours. The unsaturated fatty acids or fatty acid derivatives produced chromatographically in this manner are suitable as valuable active agents in the fields of nutrition and medicine.
Abstract: The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.
Abstract: The use of compounds of formula I as topical agents to combat the disorders of the skin produced by photodamage which disorders include: wrinkling, elastosis and premature aging is described. Compounds of formula I are ##STR1## wherein n represents 1 or 2, Z represents --SO.sub.2 R, wherein R represents lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkoxy-lower-alkyl, lower-alkanoyl-lower-alkyl, hydroxy-lower-alkyl, halo-lower-alkyl, lower-carbalkoxy-lower-alkyl, lower-alkoxy, hydroxy, mono-lower-alkyl amino or di-lower-alkylaminoand pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
May 8, 1990
Date of Patent:
June 23, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Graeme Findlay Bryce, Stanley Seymour Shapiro
Abstract: Binding assays are effected by introducing a specific binding reagent through a top absorbant membrane in parallel contact with a main absorbant membrane. By providing a parallel flow of liquid in the two membranes, and by controlling the flow of the diluted reagent from the top absorbant membrane into the main absorbant membrane, a controlled, uniform dilution of the reagent is obtained, leading to more accurate assay results.
Type:
Grant
Filed:
June 17, 1997
Date of Patent:
June 23, 1998
Assignee:
Roche Diagnostics Systems, Inc.
Inventors:
Alexei Dmitri Klimov, Shiow-Chuan Jane Tsai
Abstract: Compounds of formulas ##STR1## wherein, B is lower alkylene or an optionally substituted aromatic ring system;G.sup.1, G.sup.2 and G.sup.3 each independently signify a residue of a glycopyranoside, a glycopyranose or a derivative thereof, with at least one hydroxy group of residue G.sup.1, G.sup.2 or G.sup.3 being esterified with sulfuric acid, and pharmaceutically usable salts thereof, are useful for the treatment of disorders which are characterized by excessive or destructive proliferation of smooth muscle cells.
Type:
Grant
Filed:
April 26, 1996
Date of Patent:
June 16, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Alexander Chucholowski, Jurgen Fingerle, Niggi Iberg, Hans Peter Marki, Rita Muller, Michael Pech, Marianne Rouge, Gerard Schmid, Thomas Tschopp, Hans Peter Wessel
Abstract: The analytical device comprises a conveyor for conveying cuvettes to one or more stations for processing samples for analysis in the cuvettes. The processing stations comprise means for removing individual cuvettes from the conveyor, transferring the cuvettes to a processing position and returning the cuvettes to the conveyor after processing.
Abstract: An aqueous interferon composition which comprises an amount of interferon-alpha dissolved in water with a non-ionic detergent and benzyl alcohol in amounts sufficient to stabilize the amount of interferon-alpha, which composition contains an amount of acidic buffer which provides a pH of 4.5 to 6.0, and may also contain an isotonizing agent.
Type:
Grant
Filed:
April 4, 1996
Date of Patent:
June 9, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Gunter Gross, Sabino Del Terzo, Saran Kandakuri Kumar
Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.
Type:
Grant
Filed:
September 17, 1996
Date of Patent:
June 9, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Jean Ackermann, David Banner, Klaus Gubernator, Paul Hadvary, Kurt Hilpert, Klaus Muller, Ludvik Labler, Gerard Schmid, Thomas B. Tschopp, Hans Peter Wessel, Beat Wirz
Abstract: A process for the manufacture of polyene esters or polyene acids comprises reacting a polyene O,O-dialkylacetal of di(O,O-dialkylacetal) with a vinylketene acetal or analogue thereof in the presence of a Lewis acid, hydrolyzing the reaction mixture depending on the vinylketene acetal used, subsequently cleaving alcohol under strongly basic conditions from the polyene derivative produced at this stage and, where the desired ester or carboxy group is still not present, performing the respective conversion. Certain intermediates in this process form a further aspect of the invention. The final products are primarily carotenoids which can be used appropriately, e.g. as colorants and pigments for foodstuffs, animal products etc.
Abstract: Compounds of the formula: ##STR1## in which R.sup.1 is lower alkoxy, R.sup.2 is bromine or lower alkoxy, and R.sup.3 is aryl, heteroaryl or a group --Q--R.sup.30, wherein Q is ethylene, vinylene or ethynylene and R.sup.30 is aryl, heteroaryl, lower alkoxycarbonyl or carbamoyl;hydrolyzable esters of carboxylic acids of formula I; and pharmaceutically acceptable salts of these compounds are useful for treating infectious diseases.
Type:
Grant
Filed:
May 21, 1997
Date of Patent:
June 9, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Philippe Guerry, Synese Jolidon, Raffaello Masciadri, Henri Stalder, Rudolf Then
Abstract: Compounds of the formulaR.sup.1 --NH--A Iwherein R.sup.1 is an acyl moiety of a C.sub.12-40 aliphatic carboxylic acid, A is the residue of a oligopeptide devoid of one amino group, and --NH--A contains at least one positively charged amino acid, or derivatives thereof can be used for transferring anionic macromolecules into cells.
Type:
Grant
Filed:
November 20, 1996
Date of Patent:
June 2, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Jean-Yves Legendre, Andreas Supersaxo, Arnold Trzeciak
Abstract: Benzly-piperidine derivatives of formula I and their pharmaceutically acceptable salts are used in the control of psychotic disorders which are caused by damage to the dopamine system, especially schizophrenia. ##STR1## A is ##STR2## B is ##STR3## R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, amino, nitro, halogen, lower-alkly or lower-alkoxy. R.sup.4, R.sup.5 and R.sup.6 are independently hydrogen, nitro, halogen, lower-alkyl, lower-alkoxy, cyano, trifluoromethyl, amino, lower-alkylamino or di-lower-alkylamino. R.sup.7, R.sup.2 and R.sup.9 are independently hydrogen, amino or nitro.
Abstract: The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.
Abstract: Methods are disclosed for the production and purification of hydrophobic fusion proteins production and purification of said hydrophobic polypeptides, proteins or peptides. Homogeneous monomeric .beta.-amyloid peptide and tests for screening amyloid toxicity-inhibiting drugs using this monomeric .beta.-amyloid peptide relate to these fusion proteins.
Type:
Grant
Filed:
June 29, 1994
Date of Patent:
May 12, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Heinz Dobeli, Nicholas Draeger, Gerda Huber Trottman, Peter Jakob, Dietrich Stuber
Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
May 5, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
John Hakimi, Patricia Kilian, Perry Rosen
Abstract: N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregation and cell-cell adhesion. They are manufactured by cleaving off protecting groups in corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
May 5, 1998
Assignee:
Hoffman-La Roche Inc.
Inventors:
Leo Alig, Paul Hadvary, Marianne Hurzeler, Marcel Muller, Beat Steiner, Thomas Weller
Abstract: A process for the manufacture of methyl or ethyl 2-keto-L-gulonate by esterifying 2-keto-L-gulonic acid with methanol or ethanol continuously in the presence of an acidic ion exchanger in the temperature range between room temperature and about 80.degree. C. and with average residence times between about 10 and about 120 minutes and with superficial velocities of about 0.5 m/h to about 7.5 m/h. The esterification is advantageously carried out under slight over-pressure. The thus-manufactured esters are important intermediates for the synthesis of vitamin C and the respective esterification product can be converted directly into vitamin C by lactonization.
Abstract: Acetic acid derivatives of the formula ##STR1## wherein L, M, T and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregation and cell-cell adhesion, and are manufactured by cleaving protecting groups in the corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.
Type:
Grant
Filed:
December 1, 1994
Date of Patent:
March 10, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Leo Alig, Paul Hadvary, Marianne Hurzeler Muller, Marcel Muller, Beat Steiner, Thomas Weller
Abstract: A throwaway arrangement of reaction containers each having the same shape and dimensions for bringing about temperature cycles in a liquid mixture contained within the reaction containers. Each reaction container having a first conical wall region, and a second cylindrical wall region which at one end forms the opening of the reaction container. The thickness of the first wall region is less than the thickness of the second wall region. The opening of the reaction container is adapted to receive a cover for closing the container in gas-tight manner when placed on the opening of the reaction container. To facilitate handling and access to the liquids in the reaction containers, the arrangement reaction containers is annular, and the closure of each reaction container can be pierced by a pipetting needle.